Navigation Links
Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
Date:10/16/2009

se and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our vision to be a leader in the research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Addit
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
2. Resverlogix is Presenting at IAS HDL Workshop
3. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Resverlogix Share Option Extension
6. Resverlogix Notice of Conference Call & Webcast
7. /C O R R E C T I O N from Source -- Resverlogix Corp./
8. Industry Leaders Select Resverlogixs RVX-208
9. Resverlogixs Lead Drug Featured in Key Scientific Publication
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... Clinical, a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences ... recruitment services. The core expertise of PRC Clinical is focused on Clinical Trial ...
(Date:7/29/2015)... MA (PRWEB) , ... July 29, 2015 , ... Nearly ... of serious diseases. Yet few people realize that a rich source of these cells ... young adults, and teeth that need to be pulled to make room for braces. ...
(Date:7/28/2015)... -- People with a common form of hearing loss ... profound improvements in their hearing and understanding of speech ... multicenter study led by specialists at NYU Langone Medical ... of print in the journal The Laryngoscope July 7, researchers ... the United States implanted hybrid cochlear ...
(Date:7/28/2015)... ... July 28, 2015 , ... VetStem Biopharma will be offering weekly private guided ... local area veterinarians. , The tour and course will be given every Wednesday at ... VetStem’s Poway facility. Staff members are welcome to attend with their veterinarian as well. ...
Breaking Biology Technology:CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Tooth™ Dental Stem Cell Banking Available to their Patients 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2
... The International Executive Search Federation (IESF) is pleased to announce ... is the world,s largest retained executive search federation and is ... its global partners. The extensive network of over 65 Sanford ... enhance IESF,s presence in the USA. The expanded IESF will ...
... , PRINCETON, N.J., Sept. 22 ... development services to innovative pharmaceutical, biotechnology, generic drug and ... has joined the Company as general counsel. , ... Chris join the PharmaNet Development Group management team," commented ...
... September 22 Subsequent to the,announcement of the EU ... September,2009, the German surveillance lab in the state of ... Triffid, which,is unapproved in the EU. , ... Alert announcements,regarding the presence of FP967/CDC Triffid in food ...
Cached Biology Technology:Sanford Rose Associates Joins the International Executive Search Federation 2Christopher Brennan Joins PharmaNet Development Group as General Counsel 2Accredited Construct Specific PCR Test for Recently Detected Unapproved GM Flax/Linseed FP967/CDC Triffid Available Through Genetic ID 2
(Date:7/2/2015)... Fingerprint Cards has received an order for its ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... manufacturers in Asia . The order value ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, ...
(Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
(Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... our physical features and behavioural traits have evolved over centuries ... Darwin proposed that such traits are passed from a ... give the greatest advantage for survival, but did not have ... published this week, the Leeds team reports that a protein ...
... Wallace S. Broecker (Chicago, 1931), winner of the first edition ... Climate Change category, published an article in Science ... on the Brink of a Pronounced Global Warming?" He thus ... and to predict that by the early 21st century temperatures ...
... warned that the United States must be careful that ... to imported oil takes into account potential damage to ... in biofuels production could have far-reaching environmental and economic ... growing tension between energy and water security," said a ...
Cached Biology News:Gene evolution process discovered 2Broecker: 'What we need are tougher measures against climate change' 2Broecker: 'What we need are tougher measures against climate change' 3Rice University researchers ask if biofuels will lead to a 'drink or drive' 2
... The steadylite plus assay ... High assay sensitivity, Designed for ... Suitable for higher density microplates ... plates, Odor free, Convenient storage ...
... versatile Promega Flipper® Racks are ideal for ... small tubes. These polypropylene racks withstand extreme ... freezer storage. They may also be autoclaved ... is two-sided; one side accommodates 0.5ml microcentrifuge ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
...
Biology Products: